<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352686</url>
  </required_header>
  <id_info>
    <org_study_id>Busprione MuMoS HV</org_study_id>
    <nct_id>NCT04352686</nct_id>
  </id_info>
  <brief_title>Effects of Serotonin Agonist Buspirone on Multimodal Esophageal Stimulation in Healthy Volunteers</brief_title>
  <official_title>Effects of Serotonin Agonist Buspirone on Multimodal Esophageal Stimulation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate if buspirone, a partial 5-HT-1A receptor agonist, is able to modify esophageal
      sensitivity, assessed by the multimodal stimulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sensitivity to thermal stimulation</measure>
    <time_frame>After 30 minutes after administration buspirone</time_frame>
    <description>To detect changes in thermal stimulation for sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sensitivity to mechanical stimulation</measure>
    <time_frame>After 45 minutes after administration buspirone</time_frame>
    <description>To detect changes in mechanical stimulation for sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sensitivity to electrical stimulation</measure>
    <time_frame>After 60 minutes after administration buspirone</time_frame>
    <description>To detect changes in electrical stimulation for sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sensitivity to chemical stimulation</measure>
    <time_frame>After 75 minutes after administration buspirone</time_frame>
    <description>To detect changes in chemical stimulation for sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in positive and negative affect score</measure>
    <time_frame>At the beginning of the study and at the end of the multimodal stimulation</time_frame>
    <description>to detect change in affect of the multimodal stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in state trait and anxiety score</measure>
    <time_frame>At the beginning of the study and at the end of the multimodal stimulation</time_frame>
    <description>to detect changes in the score due to the multimodal stimulation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Buspirone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buspirone 20 mg per oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <description>Administration of buspirone to assess esophageal sensitivity</description>
    <arm_group_label>Buspirone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo to assess differences in esophageal sensitivity</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HV aged between 18 - 60 years

        Exclusion Criteria:

          -  history of psychiatric disease or a positive first degree psychiatric family history

          -  pregnancy or lactation

          -  concomitant administration of any centrally activating medication (anti-depressive
             medication, hypnotics, sedatives, anxiolytics, â€¦)

          -  medication affecting esophageal motility

          -  significant co-morbidities (neuromuscular, psychiatric, cardiovascular, pulmonary,
             endocrine, autoimmune, renal and hepatic)

          -  prior history of esophageal, gastric surgery or endoscopic anti-reflux procedure

          -  history of gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof Dr Jan Tack</investigator_full_name>
    <investigator_title>Prof Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

